Results 261 to 270 of about 1,994,828 (407)

Prolonged Survival of Anaplastic Thyroid Carcinoma: A Case Report and Literature Review. [PDF]

open access: yesClin Case Rep
Andargie DG   +6 more
europepmc   +1 more source

Interventional oncology in children: Where are we now?

open access: yesJournal of Medical Imaging and Radiation Oncology, EarlyView.
Abstract Paediatric Interventional Oncology (IO) lags behind adult IO due to a scarcity of specific outcome data. The suboptimal way to evolve this field is relying heavily on adult experiences. The distinct tumour types prevalent in children, such as extracranial germ cell tumours, sarcomas, and neuroblastoma, differ strongly from those found in ...
Premal Amrishkumar Patel   +1 more
wiley   +1 more source

Clinical Need and Research Investment for Liver Cancer in Australia

open access: yesAsia-Pacific Journal of Clinical Oncology, EarlyView.
Liver cancer incidence and mortality rates have been rising in comparison to other common cancers, but research funding has not been commensurate. ABSTRACT Aim This study aims to better understand factors driving the rising burden and costs of primary liver cancer (PLC) in Australia, identify key epidemiological trends, and ascertain investment in PLC ...
Romario Nguyen   +15 more
wiley   +1 more source

Epigenetic Regulation of DLK1-DIO3 Region in Thyroid Carcinoma [PDF]

open access: gold
Letícia Ferreira Alves   +6 more
openalex   +1 more source

Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions.

open access: yesThe Oncologist, 2016
Pierre Vanden Borre   +16 more
semanticscholar   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen   +3 more
wiley   +1 more source

DysRegNet: Patient‐specific and confounder‐aware dysregulated network inference towards precision therapeutics

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Gene regulation is frequently altered in diseases in unique and patient‐specific ways. Hence, personalised strategies have been proposed to infer patient‐specific gene‐regulatory networks. However, existing methods do not scale well because they often require recomputing the entire network per sample.
Johannes Kersting   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy